Test ID: NPAIN
Pain Clinic Drug Screen, Urine
NY State Approved 
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Useful For Suggests clinical disorders or settings where the test may be helpful
Detection and identification of drugs of abuse
This test is intended to be used in a setting where the identification of the drug is required.
Profile Information A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| DAU | Drugs of Abuse, Clin, DAU10, U | Yes | Yes |
| MSOP | Drug of Abuse, Opiate Conf, U | No | Yes |
Reflex Tests Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| DAUAM | Drug of Abuse, Amphetamine Conf, U | Yes | No |
| MSBR | Drug of Abuse, Barbiturate Conf, U | Yes | No |
| DAUBZ | Drug of Abuse, Benzo Conf, U | Yes | No |
| MSCO | Drug of Abuse, Cocaine Conf, U | Yes | No |
| MSTHC | Drug of Abuse, THC Conf, U | Yes | No |
| MSPCP | Drug of Abuse, Phencyclidine Conf U | Yes | No |
| MSMT | Drug of Abuse, Methadone Conf, U | Yes | No |
| MSPR | Drug of Abuse, Propoxyphene Conf, U | Yes | No |
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
Screening immunoassay is performed to detect the above drugs of abuse, followed by confirmation and quantification of screen-positive specimens as follows, with the exception of opiate confirmation, which is performed as part of the profile.
If the cocaine screen is >149 ng/mL then cocaine confirmation is performed at an additional charge.
If the THC screen is >49 ng/mL then THC confirmation is performed at an additional charge.
If the barbiturate screen is >199 ng/mL then barbiturate confirmation is performed at an additional charge.
If the benzodiazepine screen is >199 ng/mL then benzodiazepine confirmation is performed at an additional charge.
If the phencyclidine screen is >24 ng/mL then phencyclidine confirmation is performed at an additional charge.
If the amphetamines screen is >499 ng/mL then amphetamines confirmation is performed at an additional charge.
If the methadone screen is >299 ng/mL then methadone confirmation is performed at an additional charge.
If the propoxyphene screen is >299 ng/mL then propoxyphene confirmation is performed at an additional charge.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Method Name A short description of the method used to perform the test
DAU/501040: Enzyme-Multiplied Immunoassay Technique (EMIT)
MSOP/500365: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
MSCO/500369, MSTHC/500370, MSBR/500367, DAUBZ/500368, MSPCP/500371, DAUAM/500366, MSMT/500372, MSPR/500373: Gas Chromatography-Mass Spectrometry (GC-MS) (if appropriate)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Aliases Lists additional common names for a test, as an aid in searching
7-Amino Flunitrazepam (Metabolite of Flunitrazepam (Rohypnol)
Alprazolam (Xanax)
Amobarbital (Amytal)
Amphetamines
Amytal (Amobarbital)
Ativan (Lorazepam)
Barbiturates
Benzodiazepines
Benzoylecgonine (Cocaine Metabolite)
Butabarbital (Butisol)
Butalbital (Fiorinal)
Butisol (Butabarbital)
Cannabinoids (Tetrahydrocannabinol)
Chlordiazepoxide (Librium)
Cocaine
Codeine
Dalmane (Flurazepam)
Darvon (Propoxyphene)
Desalkyl Flurazepam (Metabolite)
Diazepam (Valium)
Dilaudid (Hydromorphone)
Dolophine (Methadone)
Drugs of Abuse
Fiorinal (Butalbital)
Flunitrazepam (Rohypnol)
Flurazepam (Dalmane)
Halcion (Triazolam)
Hycodan (Hydrocodone)
Hydromorphone (Dilaudid, Vicodin)
Hydroxy-Ethyl Flurazepam (Metabolite of Flurazepam) (Dalmane)
Lorazepam (Ativan)
Lortab (Hydromorphone)
Luminal (Phenobarbital)
Marijuana (Tetrahydrocannabinol)
MDMA (Methylenedioxymethamphetamine)
Mebaral (Mephobarbital)
Mephobarbital (Mebaral)
Methadone (Dolophine)
Methamphetamines (Desoxyn)
Methylenedioxyamphetamine (MDA)
Nembutal (Pentobarbital)
Nordiazepam (Tranxene)
Norpropoxyphene (Metabolite of Propoxyphene) (Darvon)
Opiates
Oxazepam (Serax)
PCP (Phencyclidine)
Pentobarbital (Nembutal)
Pentothal (Thiopental)
Percodan (Oxycodone)
Phencyclidine (PCP)
Phenobarbital
Propoxyphene (Darvon)
Restoril (Temazepam)
Rocket Fuel (Phencyclidine)
Rohypnol (Flunitrazepam)
Secobarbital (Seconal)
Seconal (Secobarbital)
Serax (Oxazepam)
Speed (Amphetamines)
Temazepam (Restoril)
Tetrahydrocannabinol (THC)
THC
THC (Tetrahydrocannabinol)
Thiopental (Pentothal)
Triazolam (Halcion)
Tuinal (Amobarbital and Secobarbital)
Valium (Diazepam)
Vicodin (Hydrocodone)
Xanax (Alprazolam)
Oxycodone (Oxycontin, Percodan, Percocet)
MDA (Methylenedioxyamphetaine) Metabolite for Methylenedioxyethylamphetamine (MDEA)
Metabolite for methylenedioxyethylamphetamine (MDEA)
Oxycontin (Oxycodone)
Librium (Chlordiazepoxide)
Hydrocodone (Hycodan, Vicodin)
Desoxyn (Methamphetamines)
Date Rape Drug (Rohypnol [Flunitrazepam])
Crack (Cocaine)
Coke (Cocaine)
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Container/Tube: Plastic, 60-mL urine container (Supply T313)
Specimen Volume: 30 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservatives.
3. No specimen substitutions.
Additional Information: No STATS are accepted for this procedure.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Reject Due To Identifies specimen types and conditions that may cause the specimen to be rejected
| Hemolysis | NA |
| Lipemia | NA |
| Icterus | NA |
| Other | NA |
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
| Specimen Type | Temperature | Time |
|---|---|---|
| Urine | Refrigerated (preferred) | 14 days |
| Ambient | 14 days | |
| Frozen | 14 days |
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
This profile was designed to test for and confirm the most common classes of drugs of abuse.
Opiate confirmation is performed on all specimens by liquid chromatography mass spectrometry(LC-MS/MS).
This profile uses immunoassay testing for drugs of abuse by class. All positive screening results are confirmed by gas chromatography/mass spectrometry (GC/MS).
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Negative for drugs of abuse
EMIT Screening cutoff concentration:
Amphetamines: 500 ng/mL
Barbiturates: 200 ng/mL
Benzodiazepines: 200 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Ethanol: 10 mg/dL
Methadone: 300 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Propoxyphene: 300 ng/mL
Tetrahydrocannabinol carboxylic acid: 50 ng/mL
This report is intended for use in clinical monitoring and management of patients. It is not intended for use in employment-related drug testing.
Interpretation Provides information to assist in interpretation of the test results
A positive result derived by this testing indicates that the patient has been exposed in the recent past to the drugs identified.
Positive results are definitive.
A detailed discussion of each drug detected is beyond the scope of this text. Each report will indicate the drugs identified. If a clinical interpretation is required, please contact Mayo Laboratory Inquiry.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
This report is intended for use in clinical monitoring and management of patients. It is not intended for use in employment-related drug testing.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. Tenth edition. New York, McGraw-Hill Professional, 2001
2. Porter WF: Clinical toxicology. In Teitz Textbook of Clinical Chemistry and Molecular Diagnostics. Fourth edition. St Louis, MO, Elsevier Saunders, 2006
3. Principles of Forensic Toxicology. Second edition. Washington DC, AACC Press, 2003, p 385
Method Description Describes how the test is performed and provides a method-specific reference
Opiate confirmation is performed on all specimens by liquid chromatography mass spectrometry (LC-MS/MS).
Drug classes are screened by an immunoassay technique. All positive screening results are confirmed by gas chromatography/mass spectrometry (GC/MS).(Unpublished Mayo methods)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday, Sunday
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Performing Laboratory Location The location of the laboratory that performs the test
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
80104-Drug screen, qualitative, multiple drug class method
82055-Ethanol
83925-Opiates
G0431-Drug screen, qualitative, multiple drug class method - government payers (if appropriate)
82145 x 2-Amphetamines (if appropriate)
82205-Barbiturates (if appropriate)
80154-Benzodiazepines (if appropriate)
82520-Cocaine (if appropriate)
83840-Methadone (if appropriate)
83992-Phencyclidine (if appropriate)
80299 x 2-Propoxyphene (if appropriate)
80299-Tetrahydrocannabinol carboxylic acid (if appropriate)
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
| Result ID | Reporting Name | LOINC Code |
|---|---|---|
| 11164 | Amphetamines | 8150-5 |
| 11141 | Confirmation - Opiates | 17384-9 |
| 200210 | Codeine | 16250-3 |
| 200211 | Hydrocodone | 16252-9 |
| 11301 | Barbiturates | 9426-8 |
| 11572 | Benzodiazepines | 9428-4 |
| 200212 | Hydromorphone | 16998-7 |
| 200214 | Morphine | 16251-1 |
| 11161 | Cocaine Metabolite | 3394-4 |
| 11165 | Methadone | 3774-7 |
| 200213 | Oxycodone | 16249-5 |
| 200289 | Oxymorphone | 17395-5 |
| 11570 | Opiates | 8220-6 |
| 11573 | Phencyclidine | 3937-0 |
| 11166 | Propoxyphene | 3545-1 |
| 11162 | Tetrahydrocannabinols | 3530-3 |
| 501206 | Ethanol | 5645-7 |
| 200209 | Comment | N/A |
External
link
PDF
document
Excel
document
Word
document